Table 1. Studies Evaluating the Safety of Levosimendan in Critically Ill Patients.

Study	Dose bolus	Dose infusion	Duration	Major adverse effects
Aidonidis et al. Cardiol Res Pract. 2011 [35]	0	0.05 - 0.2 µg/kg/min	72 h	No discontinuations due to adverse effects, two patients died of advanced heart failure.
Follath et al. Lancet. 2002 [38]	24 µg/kg	0.1 µg/kg/min	24 h	Hypotension, headache, hypokalemia
Kivikko et al. J Clin Pharmacol. 2002 [37]		0.05 - 0.1 µg/kg/min	7 days	No major adverse effects, no premature discontinuations
Moiseyev et al. Eur Heart J. 2002 [32]	6, 12, 24 µg/kg	0.1 - 0.4 µg/kg/min	6 h	Hypotension, myocardial rupture, headache, sinus tachycardia
Poelzl et al. Herz. 2008 [75]	6 - 12 µg/kg	0.07 - 0.2 µg/kg/min	24 h	Not reported
Silva-Cardoso et al. Rev Port Cardiol. 2009 [33]	12 µg/kg	0.05 - 0.2 µg/kg/min	24 h	Hypotension, hypokalemia